NCT03111810View on ClinicalTrials.gov

Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

May 25, 2017

Primary Completion Date

August 1, 2020

Study Completion Date

August 1, 2020

Conditions
Iatrogenic Cushing's Disease
Interventions
DRUG

AZD4017 and prednisolone

The drug AZD4017 will be given together with prednisolone 20mg daily for 7 days to compare its effects on metabolic tissues against the placebo arm where the participants will take placebo and prednisolone 20mg daily for 7 days.

DRUG

Placebo Oral Tablet and prednisolone

Placebo Oral tablet will be given together with prednisolone 20mg daily for 7 days to compare the effects on metabolic tissues of AZD4017 and prednisolone 20mg daily against the placebo arm.

Trial Locations (1)

Unknown

University of Oxford, Oxford

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

University of Oxford

OTHER

NCT03111810 - Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition | Biotech Hunter | Biotech Hunter